⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9523940 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28719593 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20304518 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20304471 | 0.97 | — | — | |
| SCHEMBL14621758 | 0.79 | TSHR (0.42) | — | |
| SCHEMBL15083848 | 0.79 | TSHR (0.42) | — | |
| SCHEMBL27732969 | 0.77 | — | — | |
| SCHEMBL14908423 | 0.77 | — | — | |
| SCHEMBL23019171 | 0.77 | — | — | |
| SCHEMBL29089183 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3756464-A1 | SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-12-30 | — | — | EP | disclosed |
| EP-3151669-B1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-10442777-B2 | Use of substituted oxadiazoles for combating phytopathogenic fungi | BASF SE (DE) | 2019-10-15 | — | — | US | disclosed |
| US-20190016694-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2019-01-17 | — | — | US | disclosed |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2017-05-25 | — | — | US | disclosed |
| EP-1436286-B1 | FUMAGILLOL DERIVATIVES AND PREPARING METHOD THEREOF | EQUISPHARM CO LTD (KR) | 2009-08-19 | — | — | EP | disclosed |
| US-20070149613-A1 | Fumagillol derivative and the medical use thereof | EQUISPHARM CO., LTD. (KR) | 2007-06-28 | — | — | US | disclosed |
| US-20060276512-A1 | Fumagillol derivatives and preparing method thereof | HAN CHEOL-KYU | 2006-12-07 | — | — | US | disclosed |
| US-7087768-B2 | 6-O-(4-methoxyaniline)acetyl fumagillol for example; superior angiogenesis inhibitory effect with less toxicity, also a cancer metastasis inhibitor, and treats angiogenesis related disorders such as other various inflammatory diseases such as rheumatic disease, psoriasis, and diabetic retinopathy | EQUISPHARM CO., LTD. (KR) | 2006-08-08 | — | — | US | disclosed |